Lentiviral Vectors and Gene Therapy
Gene therapy was conceived during the early and mid part of the 20th century. At first, it was considered a revolutionary biomedical procedure, which could potentially cure any disease for which the molecular bases were understood. Since then, gene therap
- PDF / 2,052,219 Bytes
- 110 Pages / 439.37 x 666.142 pts Page_size
- 44 Downloads / 222 Views
For further volumes: http://www.springer.com/series/10196
David Escors Karine Breckpot Frederick Arce Grazyna Kochan Holly Stephenson •
•
Lentiviral Vectors and Gene Therapy
123
David Escors Division of Infection and Immunity Rayne Institute University College University Street 5 London WC1E 6JF UK
Grazyna Kochan Structural Genomics Consortium (SGC) Oxford University of Oxford Windmill Road Oxford OX3 7HE UK
Karine Breckpot Department of Physiology–Immunology Medical School Free University of Brussels Laarbeeklaan 103 1090 Jette Belgium
Holly Stephenson University College London University Street 5 London WC1E 6JF UK
Frederick Arce University College London University Street 5 London WC1E 6JF UK
ISSN 2211-9353 ISBN 978-3-0348-0401-1 DOI 10.1007/978-3-0348-0402-8
e-ISSN 2211-9361 e-ISBN 978-3-0348-0402-8
Springer Basel Heidelberg New York Dordrecht London Library of Congress Control Number: 2012934664 Ó The Author(s) 2012 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
Writing a book about lentivectors and gene therapy was certainly a challenge. During the past decades, retroviral and lentiviral vectors have moved from just academic and basic research into human clinical trials. Thus, the enormous amount of information makes it hard to select
Data Loading...
